Proprotein convertase subtilisin/kexin type 9 inhibition in cardiovascular disease: current status and future perspectives

Proprotein convertase subtilisin/kexin type 9 (PCSK9) targets the degradation of low-density lipoprotein (LDL) receptors; it has been proved that its inhibition improves cardiovascular outcomes in patients with established atherosclerotic cardiovascular disease (ASCVD). Herein, we review the current...

Descripción completa

Detalles Bibliográficos
Autores principales: Cho, Kyung Hoon, Hong, Young Joon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Association of Internal Medicine 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7487297/
https://www.ncbi.nlm.nih.gov/pubmed/32921006
http://dx.doi.org/10.3904/kjim.2020.140

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7487297/
https://www.ncbi.nlm.nih.gov/pubmed/32921006
http://dx.doi.org/10.3904/kjim.2020.140

Ejemplares similares